Rubius Therapeutics to Announce First Quarter 2020 Financial Results

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report first quarter 2020 financial results on Monday, May 11, 2020, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 949-5296 [email protected]

Media Contact:  Dan Budwick 1AB +1 (973) 271-6085 [email protected]

You May Also Be Interested In

• Nvidia Q2 preview: a beat is a fail, a blowout is base case
• FingerMotion Notes Lyken.AI Non-Binding MOU for 128-Node B300 AI Compute Cluster
• Draganfly Appoints Brigadier General AJ Pasagian USMC (Ret’d) as President of Draganfly Defense USA Operations